Navigation Links
FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers
Date:10/17/2011

SILVER SPRING, Md., Oct. 17, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has issued a proposed rule and draft special controls guidance lowering the risk classification for external pacemaker pulse generators from Class III (high-risk) to Class II (moderate-risk).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

External pacemaker pulse generators are used temporarily to regulate a patient's heartbeat until a permanent pacemaker can be implanted. They are also used following heart surgery or after a heart attack to control irregular heartbeats.  

"The FDA has assessed the benefits and risks of external pacemaker pulse generators," said Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health (CDRH). "The special controls outlined in this draft guidance, along with general controls, will assure the safety and efficacy of these devices and provide manufacturers with a more predictable path to market."  

General controls include requirements regarding good manufacturing practice, labeling, registering all establishments with the FDA, listing all devices to be marketed and submitting a premarket notification [510(k)] before marketing a device.

However, general controls alone are insufficient to assure safety and effectiveness of Class II devices. In addition to complying with general controls, Class II devices are also subject to special controls, which may include special labeling requirements, mandatory performance standards and postmarket surveillance.

External pacemaker pulse generators are "preamendment" devices, meaning they were on the market prior to the Medical Device Amendments Act of 1976. Approximately 100 preamendment device types were classified as Class III devices, but many continued to be reviewed under the 510(k) program because the FDA did not issue regulations requiring applications for premarket approval (PMAs).

In 2009, CDRH began the process for the review of the remaining Class III preamendment device types subject to 510(k) review to determine whether to reclassify them or require PMAs.  

External pacemaker pulse generators are one of the 22 remaining Class III preamendment devices that have been regulated through the 510(k) premarket submission program, rather than the premarket approval program required for other Class III devices.  

The proposed rule and draft special controls guidance do not significantly change the FDA's review of external pacemakers pulse generators, but they do provide manufacturers with clarity and specific guidance on what information is needed in a 510(k) for these products.

For more information:

Draft Class II Special Controls Guidance Document: External Pacemaker Pulse Generator

http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm275701.htm

Proposed Rule: Reclassification of External Pacemaker Pulse Generator Devices

http://www.gpo.gov/fdsys/pkg/FR-2011-10-17/html/2011-26625.htm

515 Program Initiative

http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHTransparency/ucm240310.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices
2. FDA Proposes New Policy for Some Diagnostic and Radiology Devices
3. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
4. Mangrove Partners Proposes Fully-Financed Dividend Recapitalization to Board of CPEX Pharmaceuticals, Inc.
5. FDA Proposes Withdrawal of Low Blood Pressure Drug
6. American Association for Homecare Proposes Strong Anti-Fraud Measures in Medicare, Applauds HHS Testimony Today That Pledges to "Stop Fraud Before it Starts"
7. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
8. Cancer Cure Coalition Proposes Major Changes at the FDA
9. Prescription Drug Manufacturers Underpaid Medicaid Rebates, Federal and State Whistleblower Complaint Alleges
10. FDA Seeks Comment on Streamlined Review of Lower Risk, New Technology, Devices
11. FDA CONSUMER HEALTH INFORMATION - Concentration Lowered in Tamiflu Medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% of its original ... to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers out of ...
(Date:2/11/2016)... ROLLING MEADOWS , Ill. and INDIANAPOLIS ... major milestone for many young people, but for those ... demanding. Not only do these students juggle class schedules, ... challenges of living with type 1 diabetes. On top ... the first time. Diabetes Scholars Foundation ...
(Date:2/11/2016)... Feb. 11, 2016  AbbVie, a global biopharmaceutical ... Scholarship, designed to provide financial support for exceptional ... pursue higher education goals. Fifteen scholars will be ... school year. The AbbVie Rheumatology Scholarship is currently ... vice president, corporate social responsibility, brand and communications, ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 12, 2016 , ... The Journal ... up from 0.416 in 2013. The SJR uses data taken from the Scopus database ... both the number of citations received by the journal over a three year period ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative Health and ... for their simultaneous grand openings in March. All seven practices are set to ... wondering, is reversing diabetes possible? According to this 2011 CNN article it is ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study for Plans and ... health care system that’s partnering with Intel on value-based health benefits program Connected ...
(Date:2/11/2016)... ... , ... PharmMD CEO Robert Yeager announced today ... contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include healthcare ... breaches for the Part D Star Rating improvement and Medication Therapy Management firm. ...
(Date:2/11/2016)... Long Island, NY (PRWEB) , ... February 11, ... ... (INS) has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, ... global leader in vein illumination with an estimated 85% share of the market, ...
Breaking Medicine News(10 mins):